Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.

Soluble Type II Transforming Growth Factor-β Receptor Inhibits Established Murine Malignant Mesothelioma Tumor Growth by Augmenting Host Antitumor Immunity

Suzuki, Eiji, Kapoor, Veena, Cheung, H.-Kam, Ling, Leona E., DeLong, Peter A., Kaiser, Larry R., Albelda, Steven M. · 2004 · Clinical Cancer Research

Abstract

PURPOSE: Transforming growth factor (TGF)-beta blockade has been proposed as an anticancer therapy; however, understanding which tumor patients might benefit most from such therapy is crucial. An ideal target of such inhibitory therapy might be malignant mesothelioma (MM), a highly lethal, treatment-resistant malignancy of mesothelial cells of the pleura and peritoneum that produces large amounts of TGF-beta. The purpose of this study was to explore the possible therapeutic utility of TGF-beta blockade on MM. EXPERIMENTAL DESIGN: To evaluate this hypothesis, we tested the effects of a soluble TGF-beta type II receptor (sTGF-beta R) that specifically inhibits TGF-beta1 and TGF-beta 3 in three different murine MM tumor models, AB12 and AC29 (which produce large amounts of TGF-beta) and AB1 (which does not produce TGF-beta). RESULTS: Tumor growth of both established AB12 and AC29 tumors was inhibited by sTGF-beta R. In contrast, AB1 tumors showed little response to sTGF-beta R. The mechanism of these antitumor effects was evaluated and determined to be primarily dependent on immune-mediated responses because (a) the antitumor effects were markedly diminished in severe combined immunodeficient mice or mice depleted of CD8(+) T cells and (b) CD8(+) T cells isolated from spleens of mice treated with sTGF-beta R showed strong antitumor cytolytic effects, whereas CD8(+) T cells isolated from spleens of tumor-bearing mice treated with of control IgG2a showed no antitumor cytolytic effects. CONCLUSIONS: Our data suggest that TGF-beta blockade of established TGF-beta-secreting MM should be explored as a promising strategy to treat patients with MM and other tumors that produce TGF-beta.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-03-0611

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 59 references

Research works printed but not linked: 1

  1. Kumar-Singh S, Weyler J, Martin MJH, Vermeulen PB, Van Marck E. Angiogenic cytokines in mesothelioma: a study of VEGF, FGF-1 and -2, and TFGβ expression. J Pathol, 189: 72-8, 1999. · doi:10.1002/(sici)1096-9896(199909)189:1<72::aid-path401>3.0.co;2-0

Cited by

See all 65

Metadata

Authors
Suzuki, E., Kapoor, V., Cheung, H.-K., Ling, L. E., DeLong, P. A., Kaiser, L. R., & Albelda, S. M.
Affiliations
  • University of Pennsylvania (US)
  • Biogen (United States) (US)
  • 1Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania; and
Venue
Clinical Cancer Research
Published
2004-09-01
Volume
10
Issue
17
Pages
5907-5918
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2023961961
Cited by
65
References
59
Citations by year
2024: 1 · 2023: 1 · 2021: 1 · 2019: 2 · 2018: 2 · 2017: 4 · 2016: 1 · 2015: 2 · 2014: 2 · 2013: 5 · 2012: 7
FWCI
2.01
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
U.S. Public Health Service (P01 66726)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
malignant mesothelioma, TGF-beta blockade, antitumor immunity, CD8+ T cells, tumor growth inhibition, TGF-β1, TGF-beta3, SCID mice, tumor immunology
MeSH terms
Receptor, Transforming Growth Factor-beta Type II, Animals, Female, Genes, MHC Class II, Genes, MHC Class I, Lymphocyte Depletion, Mesothelioma, Mice, Inbred BALB C, Mice, Inbred CBA, Spleen, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, CD4-Positive T-Lymphocytes, Transforming Growth Factor beta, Mice, SCID, Protein Serine-Threonine Kinases, Receptors, Transforming Growth Factor beta, CD8-Positive T-Lymphocytes, fas Receptor, Mice, Transforming Growth Factor beta1, Transforming Growth Factor beta3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Soluble Type II Transforming Growth Factor-β Receptor Inhibits Established Murine Malignant Mesothelioma Tumor Growth by Augmenting Host Antitumor Immunity. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-03-0611
The paper
Suzuki, E., Kapoor, V., Cheung, H.-K., Ling, L. E., DeLong, P. A., Kaiser, L. R., & Albelda, S. M. (2004). Soluble Type II Transforming Growth Factor-β Receptor Inhibits Established Murine Malignant Mesothelioma Tumor Growth by Augmenting Host Antitumor Immunity. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-03-0611

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.